Friday, July 10, 2026

Drug profile · INN

ziprasidone mesylate

ziprasidone mesylate (ZIPRASIDONE MESYLATE) is a serotonin 2c (5-ht2c) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ziprasidone mesylate
US status
approved
Class
Route
INTRAMUSCULAR
Patents
0
Programs
0
Data quality
0.84

Quick answer

ziprasidone mesylate (ZIPRASIDONE MESYLATE) is a serotonin 2c (5-ht2c) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN ziprasidone mesylate
Brand ZIPRASIDONE MESYLATE
Mechanism Serotonin 2c (5-HT2c) receptor antagonist
Target D(2) dopamine receptor
Route INTRAMUSCULAR
Formulation POWDER

Mechanism of action

Serotonin 2c (5-HT2c) receptor antagonist

Primary target: D(2) dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. cabergoline Dopamine D2 receptor agonist
  4. clozapine Serotonin 2a (5-HT2a) receptor antagonist
  5. fluphenazine decanoate Dopamine D2 receptor antagonist
  6. fluphenazine hydrochloride Dopamine D2 receptor antagonist

Frequently asked questions

What is ziprasidone mesylate?

ziprasidone mesylate (ZIPRASIDONE MESYLATE) is a serotonin 2c (5-ht2c) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for ziprasidone mesylate?

ZIPRASIDONE MESYLATE is a marketed brand name for ziprasidone mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ziprasidone mesylate?

ziprasidone mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.